CD48 as a novel target in asthma therapy.

Ariel Munitz*, Ido Bachelet, Francesca Levi-Schaffer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


CD48, a CD2-related surface molecule, emerges as a critical effector molecule in immune responses. CD48 has a striking array of biological functions, among them adhesion, pathogen recognition, cellular activation, and cytokine regulation. Still, it is surprising that this mysterious molecule has not yet met its proper use as a therapeutical target in exaggerated immune disorders like hematopoietic tumors, autoimmunity and allergic reactions. Recently, CD48 was investigated in our laboratory as an effector molecule in human eosinophil function and in asthma. In this review, we shall discuss the known aspects of CD48 biology and describe the recent advances regarding the role of CD48 in human disease. Moreover, we shall review inventions making use of CD48, and discuss recent patents and the potential of CD48 as a future target for the therapy of allergic and other diseases.

Original languageAmerican English
Pages (from-to)9-12
Number of pages4
JournalRecent Patents on Inflammation and Allergy Drug Discovery
Issue number1
StatePublished - 2007


Dive into the research topics of 'CD48 as a novel target in asthma therapy.'. Together they form a unique fingerprint.

Cite this